RxDoctor Payments Data

Niraj Choudhary, MD

Internal Medicine · Webster, TXNPI 1013906684

Payments from drug & device makers

$2,948in general payments, 2019–2025

Across 163 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$419
  • Novo Nordisk$359
  • AbbVie$345
  • Amgen$340
  • AstraZeneca$268
  • Novartis$158
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,91799%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,948 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$309,633
Medicare patients
451
Services billed
5,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$85,882
OzempicSemaglutide62$67,332
FarxigaDapagliflozin Propanediol54$59,934
JardianceEmpagliflozin37$39,267
TradjentaLinagliptin19$26,606
XareltoRivaroxaban22$23,126
JanuviaSitagliptin Phosphate12$20,244
MounjaroTirzepatide15$15,379
TrulicityDulaglutide15$15,367
Repatha SureclickEvolocumab17$14,791
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,894
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$9,064
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$4,342
Albuterol Sulfate HfaAlbuterol Sulfate124$3,308
Atorvastatin Calcium305$3,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$95$85,88287 claims
Novo NordiskOzempic$359$67,33262 claims
Boehringer IngelheimJardiance, Tradjenta$76$65,87356 claims
AstraZenecaFarxiga$268$59,93454 claims
Lilly USA, LLCMounjaro, Trulicity$419$30,74630 claims
Johnson & JohnsonXarelto$81$23,12622 claims
GSKTrelegy Ellipta$66$9,89413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →